Bayer adds menopause drug to pipeline with KaNDy acquisitionBayer is to buy UK-based KaNDy Therapeutics in a deal worth more than $800 million, adding the biotech’s Share XBayer adds menopause drug to pipeline with KaNDy acquisitionhttps://pharmaphorum.com/news/bayer-adds-menopause-drug-to-pipeline-with-kandy-acquisition/
Astellas pushes non-hormonal menopause drug into phase 3Japan’s Astellas has started treating patients in a phase 3 trial of fezolinetant, a non-hormonal drug for menopausal Share XAstellas pushes non-hormonal menopause drug into phase 3https://pharmaphorum.com/news/astellas-pushes-non-hormonal-menopause-drug-into-phase-3/
